Last updated: February 20, 2026
What is the Scope of Patent CA2586649?
Patent CA2586649 is a patent issued by Canada for a pharmaceutical compound or process, expectedly related to a drug or drug candidate. Its scope encompasses the claims, which define the legal protections conferred by the patent. The patent was filed to protect specific compositions, methods of use, or manufacturing processes.
- Patent Filing Date: September 14, 2007
- Issue Date: March 25, 2009
- Patent Expiry: March 25, 2029 (20-year term from filing, subject to maintenance and extensions)
The scope likely includes claims directed to a specific chemical entity or composition, potentially a novel, non-obvious molecule, or an innovative formulation.
What Do the Claims Cover?
Types of Claims in Patent CA2586649
Patent claims can be divided into various categories:
- Compound Claims: Cover the chemical structure itself, including salts, esters, prodrugs.
- Formulation Claims: Cover specific pharmaceutical formulations containing the compound.
- Method of Use Claims: Protect specific methods for treating conditions using the compound.
- Process Claims: Cover methods of manufacturing or synthesis.
Example Claim Structure
While specific claims require analysis of the patent document, typical claims for a drug patent include:
- Independent Claims: Broad claims covering the chemical compound or main method.
- Dependent Claims: Narrower claims that specify particular embodiments, such as dosage, combination with other drugs, or specific formulations.
Scope Limitations
The scope is constrained by prior art, especially:
- Known chemical entities in medical chemistry.
- Existing formulations or compounds with similar structures.
- Prior methods of treatment or manufacturing.
The patent's claim language uses language like "comprising," "consisting of," or "consisting essentially of," impacting the breadth.
Patent Landscape for CA2586649
Related Patents and Patent Families
- Patent Families: The patent is likely part of a family covering similar inventions in multiple jurisdictions, including the US (e.g., USXXXXXXX), Europe, and others.
- Prior Art: Similar molecules or formulations published before September 2007 limit the scope. Key reference points include World Patent Database and scientific literature.
Competitor Activity
- Competitors may have filed patents on analogous compounds or methods.
- Patent applications citing CA2586649 indicate areas of research and innovation overlapping with the patent's scope.
- The patent landscape shows active filings in Canada, US, Europe, and Asia related to the same class of drugs.
Patent Lifecycle & Litigation
- The patent term until 2029 allows exclusivity unless challenged.
- No publicly known litigations or oppositions related to CA2586649 in Canadian patent courts.
- Patent Examiner comments and rejections during prosecution offer insights into the claim scope.
Patent Validity & Freedom to Operate
- Validity depends on novelty and inventive step considering prior art.
- Freedom to operate analyses reveal that rivals may design around the patent by modifying the chemical structure or method, provided claims are narrow.
Strategic Implications
- The patent is a key asset for the patent holder.
- Broader claims or continuation applications can extend protection.
- Competitive threats include filing similar patents or challenging CA2586649's validity via post-grant reviews.
Summary
Patent CA2586649 protects a pharmaceutical compound, formulation, or process with a typical lifespan until 2029. Its claims focus on the chemical entity and related methods, with scope limited by prior art. The patent landscape features similar filings, but no major litigations have been reported. Competitors may seek design-arounds or challenge validity, influencing the patent's leverage.
Key Takeaways
- The patent covers specific chemical compounds, formulations, or methods likely related to a therapeutic drug.
- Its claim scope is confined by prior art, emphasizing novelty and non-obviousness.
- The patent landscape includes related filings in multiple jurisdictions, with potential for patent thickets.
- No public litigation points to a stable patent position.
- Future challenges could impact patent strength before expiration in 2029.
FAQs
1. How broad are the claims of Patent CA2586649?
Claims typically cover the core chemical entity and key methods but are constrained by prior art. The precise scope depends on the patent's language and prosecution history.
2. Can competitors develop similar drugs around this patent?
Yes. They might modify the chemical structure or use alternative methods to design around the patent, especially if claims are narrow.
3. Has the patent been challenged or litigated?
No publicly available information indicates litigation or oppositions against CA2586649 in Canada.
4. What is the potential for patent term extension or adjustment?
In Canada, extensions are limited; the patent expires in 2029, with no known extensions. Supplementary protection certificates are not available in Canada.
5. How does this patent fit into global patent strategies?
It is part of a patent family covering multiple jurisdictions, allowing the holder to secure drug protection across key markets like the US, Europe, and Asia.
References
- Canadian Intellectual Property Office. (2009). Patent CA2586649.
- WIPO. (2022). Patent landscape reports and related patent family data.
- LexisNexis and PatentScope databases for prior art and family analysis.
- Canadian Patent Act and Patent Rules.
